Institute of Neuropathology, University Hospital Zurich, Switzerland.
Acta Neuropathol. 2012 Nov;124(5):705-16. doi: 10.1007/s00401-012-1020-6. Epub 2012 Jul 28.
Accumulation of the DNA/RNA binding protein fused in sarcoma (FUS) as inclusions in neurons and glia is the pathological hallmark of amyotrophic lateral sclerosis patients with mutations in FUS (ALS-FUS) as well as in several subtypes of frontotemporal lobar degeneration (FTLD-FUS), which are not associated with FUS mutations. Despite some overlap in the phenotype and neuropathology of FTLD-FUS and ALS-FUS, significant differences of potential pathomechanistic relevance were recently identified in the protein composition of inclusions in these conditions. While ALS-FUS showed only accumulation of FUS, inclusions in FTLD-FUS revealed co-accumulation of all members of the FET protein family, that include FUS, Ewing's sarcoma (EWS) and TATA-binding protein-associated factor 15 (TAF15) suggesting a more complex disturbance of transportin-mediated nuclear import of proteins in FTLD-FUS compared to ALS-FUS. To gain more insight into the mechanisms of inclusion body formation, we investigated the role of Transportin 1 (Trn1) as well as 13 additional cargo proteins of Transportin in the spectrum of FUS-opathies by immunohistochemistry and biochemically. FUS-positive inclusions in six ALS-FUS cases including four different mutations did not label for Trn1. In sharp contrast, the FET-positive pathology in all FTLD-FUS subtypes was also strongly labeled for Trn1 and often associated with a reduction in the normal nuclear staining of Trn1 in inclusion bearing cells, while no biochemical changes of Trn1 were detectable in FTLD-FUS. Notably, despite the dramatic changes in the subcellular distribution of Trn1 in FTLD-FUS, alterations of its cargo proteins were restricted to FET proteins and no changes in the normal physiological staining of 13 additional Trn1 targets, such as hnRNPA1, PAPBN1 and Sam68, were observed in FTLD-FUS. These data imply a specific dysfunction in the interaction between Trn1 and FET proteins in the inclusion body formation in FTLD-FUS. Moreover, the absence of Trn1 in ALS-FUS provides further evidence that ALS-FUS and FTLD-FUS have different underlying pathomechanisms.
融合肉瘤(FUS)相关 DNA/RNA 结合蛋白在神经元和神经胶质中的包涵体的积累,是肌萎缩性侧索硬化症(ALS)伴 FUS 突变(ALS-FUS)以及几种非 FUS 突变相关的额颞叶变性(FTLD-FUS)亚型患者的病理学标志。尽管 FTLD-FUS 和 ALS-FUS 的表型和神经病理学有一些重叠,但最近在这些疾病的包涵体的蛋白质组成中发现了具有潜在病理机制相关性的显著差异。虽然 ALS-FUS 仅显示 FUS 的积累,但 FTLD-FUS 中的包涵体揭示了 FET 蛋白家族所有成员的共同积累,包括 FUS、尤因肉瘤(EWS)和 TATA 结合蛋白相关因子 15(TAF15),这表明与 ALS-FUS 相比,FTLD-FUS 中转运蛋白介导的蛋白质核输入更复杂的紊乱。为了更深入地了解包涵体形成的机制,我们通过免疫组织化学和生物化学方法研究了 Transportin 1(Trn1)以及 Transportin 的 13 种其他货物蛋白在 FUS 病变谱中的作用。包括四个不同突变在内的六个 ALS-FUS 病例中的 FUS 阳性包涵体未标记 Trn1。与此形成鲜明对比的是,所有 FTLD-FUS 亚型的 FET 阳性病理学也强烈标记 Trn1,并且经常与包涵体携带细胞中正常核染色的 Trn1 减少相关,而在 FTLD-FUS 中未检测到 Trn1 的生化变化。值得注意的是,尽管 FTLD-FUS 中转运蛋白 Trn1 的亚细胞分布发生了巨大变化,但它的货物蛋白的改变仅限于 FET 蛋白,并且在 FTLD-FUS 中未观察到 13 种额外的 Trn1 靶标(如 hnRNPA1、PAPBN1 和 Sam68)的正常生理染色发生改变。这些数据表明,在 FTLD-FUS 的包涵体形成中,Trn1 与 FET 蛋白之间的相互作用存在特定的功能障碍。此外,ALS-FUS 中缺乏 Trn1 进一步证明 ALS-FUS 和 FTLD-FUS 具有不同的潜在病理机制。